Literature DB >> 9141740

Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus.

L A Selvey1, M Denton, A J Plant.   

Abstract

The objective of this study was to describe the incidence and prevalence of hepatitis C infection among clients of a methadone program in Queensland. The clinical notes of clients receiving methadone for treatment of opiate dependence who first registered at the clinic after 1989 were perused for information about their serological status for hepatitis C and hepatitis B infections during a six-week period in 1994. We followed hepatitis C negative clients until August-September 1995. At study entry, 69 per cent of the clients were recorded as being hepatitis C positive. Of those who were negative, the seroconversion rate was 11 per 100 person-years. The high incidence and prevalence of hepatitis C among methadone clients emphasises the need for effective early intervention strategies to prevent the transmission of hepatitis C among injecting drug users.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141740     DOI: 10.1111/j.1467-842x.1997.tb01664.x

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  11 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 2.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

3.  Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area.

Authors:  H Thiede; H Hagan; C S Murrill
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

4.  Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China.

Authors:  Wang Zhou; Xia Wang; Sheng Zhou; Nianhua Xie; Pulin Liu; Li Luo; Jinsong Peng; Manqing Liu; Alethea Desrosiers; Richard Schottenfeld; Marek C Chawarski
Journal:  Addiction       Date:  2015-01-22       Impact factor: 6.526

5.  Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use.

Authors:  Courtney L C Collins; Thomas Kerr; Laura M Kuyper; Kathy Li; Mark W Tyndall; David C Marsh; Julio S Montaner; Evan Wood
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

Review 6.  Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Authors:  David M Novick; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04-16       Impact factor: 6.526

7.  Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B.

Authors:  Gavin Bart; Paola Piccolo; Linqi Zhang; Ira Jacobson; Robert A Schaefer; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04       Impact factor: 6.526

8.  Substance use and hepatitis C: an ecological momentary assessment study.

Authors:  Karran A Phillips; David H Epstein; Massoud Vahabzadeh; Mustapha Mezghanni; Jia-Ling Lin; Kenzie L Preston
Journal:  Health Psychol       Date:  2014-07       Impact factor: 4.267

9.  Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance.

Authors:  Jessica Willner-Reid; Katherine A Belendiuk; David H Epstein; John Schmittner; Kenzie L Preston
Journal:  J Subst Abuse Treat       Date:  2007-10-10

10.  A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users.

Authors:  Nat M J Wright; Charlotte N E Tompkins
Journal:  Harm Reduct J       Date:  2006-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.